Article | August 5, 2020

Improving Lentiviral Vector Downstream Processing Workflows

Source: Cytiva
Cytiva akta pure plus screen_28516-m14Aug20

Article inspired by a Tapas and TechTalks digital event. Fast Trak Centre for Advanced Therapeutic Cell Technologies (CATCT) team members shared insights from customer collaborations.

Lentiviral vectors (LVV) are a common vehicle to deliver genetic material in CAR T cell therapy and gene therapy applications. Production methods have been developed by adapting technologies from the bioprocessing sector. However, these downstream workflows are long, require substantial manual labor, and suffer from low yields of infectious virus. In this article we discuss process development pain points of a modern workflow and ways to address them. We look at new technologies that may be applicable to cell and gene therapy as well as older technologies that have proven very valuable in bioprocessing and can be adapted to serve similar functions in cell and gene manufacturing.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: